Get started

Fdaapproval

PHAT Phantom Pharma to moonshot from upgrade LONGPHAT is now targeting 25-34 according to analysts. I am not surprised. It has a pipeline and is pending approval for a medication product to treat a stomach bacteria that causes chronic infection and symptoms are often refractory to long and elaborate treatment protocols. The product is already in Asia and doing well in YoY reports. PHAT has partnered with another pharma company to make regulatory and marketing inroads in the European market. My portfolio is already heavy with medtech and pharma but this one is far to promising with the great upside it presents. I will hit this one hard trying to get the low of day in pieces and build a position.
NASDAQ:PHATLong
by AwesomeAvani
TSHA a medtech penny stock pumps on news and earnings LONGTSHA is a gene technology medical company which reported on its clinical trials for Rett Syndrome which is a neurobehavioral disorder separate from others like autism or schizophrenia. This could be a breakthrough medication for those who suffer from Rett. TSHA102 could be heralded as a miracle treatment ( not a cure). Price had trended up in February and then down in March and is now situated at the mean anchored VWAP. Relative volumes are 5-10X the running mean. I am taking a sizeable position here based also on my background as well as the forecasts of medical technology stocks as being hot right now especially small caps. Risk is definitely on. TSHA has been selling off parts of its pipeline to fortify its core. This tells me leadership is realistic and has a survival plan which is a big plus in the world of young and small medical technology companies. The earnings report from yesterday showed a big earnings beat and a transition from cash burning to positive earnings. Part of this is from selling off part of its future. Nonetheless, that future may be very bright with what remains. I believe that TSHA will consolidate and gain consensus as to fair value but then resume bullish continuation. This may be a buy and hold until the next earnings while watching for clinical trial news that will give a hint as to the growth path.
NASDAQ:TSHALong
by AwesomeAvani
SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up 60% of its price while breaking out through the anchored VWAP lines and the volume profile. The far greater market is the former. It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the last clinical trial getting a report and a calendared review by the, SRZN could reach for that all time high. This is speculative and risky as are most biotechnology penny stocks. They are trading news and potential not current net revenues. A small position with room in the stop loss for the average range and volatility is best. This is a typical high risk higher potential reward type of trade.
NASDAQ:SRZNLong
by AwesomeAvani
$RAIN Squeeze Target we are pumping 35%+ in the premarket over our past resistant below the 5$, now is our support , we going to see a potential resistant and selling pressure below 7.80$, if we did we need to see buying pressure happing above the 6.18$, to confirm the breaking for that resistant the next time, and continue to go up to the next price target around the 11.50$. if we went below the 6.18$, that's mean the short are heavily positioned at 7.80$, and we going to see strong buying pressure above the 5$, cause that's the last support we should have to confirm the bullish momentum , and reversal from the bearish trend that been happing since the last September last year
RLong
by TRADING-JESUS
CRXT 900% Upside Potential According to this analyst Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male. On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current price. I think it can easily double. Looking forward to read your opinion about it.
CLong
by TopgOptions
AYTU All Time Low | Fast Track Designation form FDA todayAYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is imminent. My price target is $5.25. Looking forward to read your opinion about it.
NASDAQ:AYTULong
by TopgOptions
1
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. My price target is the 12usd resistance.
NASDAQ:QNRXLong
by TopgOptions
4
ARDX 500mil Revenue Forecasts for a Penny Stock | The 10X call??Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NASDAQ:ARDXLong
by TopgOptions
1
ACXP cheaper than the public offeringAcurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company successfully completed Phase 1 and Phase 2a clinical trials of ibezapolstat and in the second half of 2021. (prnewswire.com)
NASDAQ:ACXPLong
by TopgOptions
Familiar T/A on ITRM Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug Administration. Currently, the NDA is still under review by the FDA, and the PDUFA goal date is July 25th, 2021. Since the application review for Sulopenem is on track at the moment, ITRM stock is performing well as a result. ITRM stock price has nearly doubled in the last month." Not sure if it gets the approvals necessary but "buy the rumor" might be playing a role here. Quote Source: Top 9 Penny Stocks With High Volume to Watch Right Now
NASDAQ:ITRM
by PennyStocks101
2
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves 1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20 -Being the end of the trading week I suspect the latter. 2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket' -Bounce off strong support at 2.00 mark -MACD is starting to squeeze but if we find momentum next week we could start to spread again. -PAR loves the .5 Fibonacci Retracement level. (Short term fact) -We hit the deeper uptrend and continue back up towards the 2.80 mark to test a strong EQ Resistance Level. Very Possible -It regains buyer momentum in the 'Golden Pocket' between the .5-.618 Fib Level. Very Possible -Positive news released early next week bring strong buying sentiment back into the market and create an Higher Low ready for the next leg up. 3. We BREAK both uptrend trendlines creating NEW Bearish Market Structure and head for the next Major Support @ 1.48 Another company im keeping a close eye on. PARADIGM BIOPHARMACEUTICALS LTD is a late stage drug development company with their aim to treat musculoskeletal disorders in humans with degenerative disease driven by injury, viral infection, aging or genetic predisposition. They have a cash balance sheet of $108 Million (06/04/20), FDA Approval, IP Protection & Patents, Agreements that stand for 20 years regarding manufacturing, Fully funded until 2022. EYES ON!!! These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:PAR
by Trader_Johnni
3
CVS PHARMACY IS FILLING SCRIPTS FOR PALFORZIA - STRONG BUYWe just checked pharmacies around the North East PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States. Its parent company ranks as the 7th largest U.S. corporation by FY2017 revenues in the Fortune 500. The parent company of CVS Pharmacy's leading competitor (Walgreens) ranked 19th for the same time period. The stupid brokerage firms that just downgraded the stock price today because of a "so called slow roll-out" have no clue what they're doing or saying anymore. All these analysts had to do is pickup the phone and call around like we did! They're lazy!!! ANyone on this board wondering how easy it is to find out, call a CVS Pharmacy and ask them if they can fill a script for PALFORZIA, they will tell you YES,,, it is in the database for them to order..!!! We are passing along our research to some major brokerage firms so they will get behind the stock and push it up Palforzia Peanut Allergy Drug is available at CVS Pharmacy and soon to be available at Walgreens and other pharmacies throughout the USA This stock could blast off any day folks! We do not buy drug stocks so we are sitting on the sidelines just passing along solid and reliable information Factual information for this board is always a good thing to post especially since you don't get it from dumb analysts! DISCLAIMER This website and our posts are for general information only. No information, forward looking statements, or estimations presented herein represent any final determination on investment performance. While the information presented in this website and our posts has been researched and is thought to be reasonable and accurate, any investment is speculative in nature. StockKid, and/or our agents cannot and do not guarantee any rate of return or investment timeline based on the information presented herein. By reading and reviewing the information contained in this website and our posts, the user acknowledges and agrees that StockKid, and/or our agents do not assume and hereby disclaim any liability to any party for any loss or damage caused by the use of the information contained herein, or errors or omissions in the information contained in this website or our posts, to make any investment decision, whether such errors or omissions result from negligence, accident or any other cause. Investors are required to conduct their own investigations, analysis, due diligence, draw their own conclusions, and make their own decisions. Any areas concerning taxes or specific legal or technical questions should be referred to lawyers, accountants, consultants, brokers, or other professionals licensed, qualified or authorized to render such advice. In no event shall StockKid, and/or our agents be liable to any party for any direct, indirect, special, incidental, or consequential damages of any kind whatsoever arising out of the use of this website, our posts or any information contained herein. StockKid, and/or our agents specifically disclaim any guarantees, including, but not limited to, stated or implied potential profits, rates of return, or investment timelines discussed or referred to herein.
ALong
by UnknownUnicorn3159981
BXRX FDA approval lotto playThis idea comes from recent success in a Sprint trade. It was slow in coming, but it did come through very successfully, which is the impetus for this idea of "reading" tickers with binary events. This is purely a news driven idea in which there is no technical reading of the chart what-so-ever. I have no idea if this will be correct, and am really using this platform for journaling & finding others who use similar methods. I'm getting the tickers from a freely available online calendar with the PDUFA dates. I use a pendulum and cards I made up to gain information on the "energy" of the situation. Anyone doing anything similar, please contact me to share information. I'm definitely on the fringes here. BXRX has a deadline for an FDA approval tomorrow (2/20/20). My indications are that it is APPROVED. I don't read about the details of the application and I don't care, although reading it may help my insomnia ;) BXRX is currently trading at the LOD $7.88 - 5.97% Indications are it could go up to $9.14 The ATH is $9.60 We shall see...
BLong
by JenRz
5
LCI may start to climb after today's FDA approvalLannett stock has struggled lately due to opioid litigation and a weakening of its earnings forecast back in November. However, the company announced several product launches in December and early January, and today Lannett got FDA approval for, of all things, a cocaine-based anesthetic nasal spray. The stock has shown little positive reaction to any of this news, but that might change if analysts start to adjust their earnings forecasts to reflect the new product offerings. Despite its underwhelming reaction to the news today, I think Lannett may start to show momentum this week as investors digest the announcement from today. Lannett has an attractive forward P/E of 6.84 and a history of beating analyst expectations on its earnings reports. Its last round of guidance was neutral, with increased administrative and sales costs offset by decreased tax burden and interest expense. Lannett should have enough cash on hand to cover its product launches thanks to a convertible notes offering last year. It has about $100 million in cash per its last earnings report, although with apparently $66 million in debt due toward the end of this year.
LLong
by ChristopherCarrollSmith